The Wiki

wiki library

The Wiki contains all the articles on the web site. The articles are put into categories and 'tagged' for easier searching.

A brisk walk is just as good as a jog when it comes to fighting nonalcoholic fatty liver disease

By craig@cnlpcb.com | July 7, 2016
Posted in
brisk walk

Moderate and vigorous exercise have comparable effects on nonalcoholic fatty liver disease Date: July 6, 2016 Source: Tulane University Summary: A brisk walk is just as good as a jog when it comes to fighting nonalcoholic fatty liver disease, researchers finds. Nonalcoholic fatty liver disease has been associated with an increased risk of cardiovascular disease…

Turmeric for Hepatitis C, Liver Disease and Beyond

By craig@cnlpcb.com | July 7, 2016
Posted in , ,
turmeric

The foods you choose to consume can benefit a liver with Hepatitis C – or it can be harmful. Living with the Hepatitis C virus, or any type of chronic liver disease, is a constant reminder of this fact. The more educated we become on which foods are the most beneficial to the liver, the…

FDA approves first pill to treat all forms of hepatitis C

By craig@cnlpcb.com | July 7, 2016
Posted in ,
epclusa tablet

Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the combination pill, Epclusa, from Gilead Sciences, for patients with and without liver damage. The new…

Can Diabetes Cause Cirrhosis?

By craig@cnlpcb.com | July 6, 2016
Posted in ,
questions

Can Diabetes Cause Complications to the Liver and Kidneys written by: DulceCorazon • edited by: Diana Cooper • updated: 8/23/2010 Can diabetes cause liver and kidney issues? Uncontrolled diabetes is known to cause diabetic nephropathy. But liver disease? Find out. Overview Can diabetes cause liver and kidney issues? This is a common question among diabetics.…

Now There Are Many (Stages)

By craig@cnlpcb.com | July 6, 2016
Posted in ,
cirrhosis

Now There Are Many (Stages) Where Before There Was One: In Search of a Pathophysiological Classification of Cirrhosis Guadalupe Garcia-Tsao,1 Scott Friedman,2 John Iredale,3 and Massimo Pinzani4 For more than a century and a half, the description of a liver as “cirrhotic” was sufficient to connote both a pathological and clinical status, and to assign…

How coffee could be your liver's savior

By craig@cnlpcb.com | June 23, 2016
Posted in , , , ,
coffee

How coffee could be your liver’s savior: Drink shown to protect against a host of deadly diseases Drink may protect against certain cancers that affect the womb and liver World Health Organisation says no link between coffee and bladder cancer New research concludes that coffee protects against fatty liver disease, liver fibrosis and liver cirrhosis…

Federal Standard May Be Thwarting Some Liver Transplant Patients

By craig@cnlpcb.com | June 9, 2016
Posted in ,
transplant

Federal Standard May Be Thwarting Some Liver Transplant Patients By EDITOR • JUN 7, 2016 Did revised federal standards make transplant centers more averse to risk and encourage them to drop sicker patients who might affect the hospitals’ patient survival rates? Originally published on June 9, 2016 4:47 pm For the roughly 15,000 people who…

Changes to MELD score to include serum sodium

By craig@cnlpcb.com | June 8, 2016
Posted in ,
meld scores

(Confusing at first glance but the numbers in the squares show how much your current meld score will go up dependent upon your serum sodium value.) Effective Date Jan 11 2016 NOV 16, 2015 | LIVER/INTESTINE, TRANSPLANT CENTER   New Resources Available for Liver Transplant Programs On January 11, 2016, OPTN Policy 9.1 (MELD Score) will…

FDA Clears Obeticholic Acid for Primary Biliary Cholangitis

By craig@cnlpcb.com | May 31, 2016
Posted in ,
clinical trials

The US Food and Drug Administration (FDA) has granted accelerated approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic (UDCA) in adults who fail to respond adequately to UDCA, or as monotherapy in adults who cannot tolerate UDCA. Last month, the FDA’s Gastrointestinal Drugs…

UDCA fails to improve mortality in primary biliary cholangitis

By craig@cnlpcb.com | April 15, 2016
Posted in ,
ursodeoxycholic acid

April 13, 2016 BARCELONA — The use of ursodeoxycholic acid for primary biliary cholangitis failed to reduce all-cause mortality, according to results of a systematic review presented at the International Liver Congress 2016. “Based on current evidence, the treatment of primary biliary cholangitis with ursodeoxycholic acid can neither be supported nor rejected,” Jelena Nincevic, MD,…